Home/Pipeline/INPEFA (sotagliflozin)

INPEFA (sotagliflozin)

Heart Failure

ApprovedCommercialN/A

Key Facts

Indication

Heart Failure

Phase

Approved

Status

Commercial

Company

Lexicon Pharmaceuticals

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals has successfully transitioned from a discovery-focused research organization to a commercial-stage biopharma company following the FDA approval of INPEFA® for heart failure in May 2023. Its core strategy is built upon a systematic, genetics-driven discovery platform that validates novel drug targets in vivo, aiming to de-risk development and deliver first-in-class therapeutics. The company's mission is to address significant unmet medical needs, with current efforts centered on commercializing INPEFA and advancing late-stage candidates like LX9211 for neuropathic pain. Lexicon's future hinges on executing its commercial launch, expanding INPEFA's label, and translating its unique platform into additional high-value clinical assets.

View full company profile

Therapeutic Areas

Cardiometabolic Neuropathic Pain

Other Heart Failure Drugs

Drug	Company	Phase	Status
Cardiac Cell Therapy Program	StemCardia	Pre-clinical	Active
NTP42	ATXA Therapeutics	Preclinical	Platform potential identified
Heart Failure Trial	Clinical Investigation Specialists	Not Specified	Actively Recruiting
MyCardia™	Avery Therapeutics	Pre-clinical	Active
Cardiac Assist Device	Second Heart Assist	Pre-clinical	Active
Isosorbide Dinitrate/Hydralazine HCl Tablets	i3 Pharmaceuticals	Approved	Active
TLT-101	TikkunLev Therapeutics	Pre-clinical	Active
Undisclosed Heart Regeneration Program	Animatus Biosciences	Pre-clinical	Active
AFteR Registry	Occlutech	N/A (Registry)	Active
biotx.ai Target Discovery Collaboration	HeartBeat.bio	Pre-clinical	Active
Surlorian	RyCarma Therapeutics	Phase 2	Active
Coronary Sinus Reduction	Shockwave Medical	Unknown	Active